List view / Grid view




HerpV and GEN-003 will drive genital herpes treatment market growth to 2023

21 July 2015 | By Victoria White

The global market value for genital herpes therapeutics will increase from approximately $490 million in 2013 to just under $668 million by 2023, largely driven by the introduction of therapeutic vaccines, HerpV and GEN-003, towards the end of the forecast period, says research and consulting firm GlobalData.